摘要
目的探讨齐拉西酮与阿立哌唑治疗首发精神分裂症的临床疗效和安全性。方法将59例首发精神分裂症患者随机分为两组，齐拉西酮组29例，口服齐拉西酮治疗，阿立哌唑组30例，口服阿立哌唑治疗。观察6周。于治疗前及治疗第2周、4周、6周末采用阳性与阴性症状量表、副反应量表评定临床疗效及不良反应。结果治疗2周末，两组阳性与阴性症状量表总分及阳性症状、一般病理因子分均较治疗前有显著下降（P〈0．01），4周末阴性症状较治疗前有显著下降（P〈0．01），同期两组间评分差异均无显著性（P〉0．05）；治疗6周末，齐拉西酮组有效率为79．3%，阿立哌唑组为80．0％，两组差异无显著性（X^2=0．004，P〉0．05）。两组不良反应发生率低，程度较轻微，差异无显著性（X^2=0．141，P〉0．05）。结论齐拉西酮与阿立哌唑治疗首发精神分裂症疗效显著，对阴性、阳性症状及一般精神病理症状均有效，起效快，安全性高，依从性好。
Objective To explore the clinical efficacy and safety of ziprasidone vs. aripiprazole in the treatment of first-episode schizophrenia. Methods Fifty-nine first-episode schizophrenia patients were randomly assigned to ziprasidone （n=29） and aripiprazole goupr （n=30） for six weeks. Clinical efficacies were assessed using the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treat- ment Emergent Symptom Scale （TESS） before treatment and at the end of the 2^nd, 4^th and 6^th week. Results At the end of the 2^nd week, the total, positive symtptom and general pathological factor scores of both groups lowered more significantly compared with pretreatment （P〈0.01） ,so did negative symptom scores at the end of the 4th week （P〈0.01）, there were no significant differences in contemporary group comparisons （P〉0.05） ; at the end of the 6th week, effective rate had no significant difference （ziprasidone 79.3% vs. aripiprazole 80%, X^2=0. 004,P〉0.05）. Incidences of adverse reactions of both groups were lower and their degrees mild, and differences were not significant （X^2=0. 141, P〉0.05）. Conclusion Both ziprasidone and aripiprazole have significant curative effects in the treatment of the first-episode schizophrenia, are effective in negative, positive and general pathological symptoms, take effect quickly, have higher safety and better compliance.
出处
《临床心身疾病杂志》
CAS
2011年第5期411-413,共3页
Journal of Clinical Psychosomatic Diseases
